Zotatifin

DRUG3 trials

Sponsors

Dana-Farber Cancer Institute, Effector Therapeutics, Jennifer Lee Caswell-Jin

Conditions

Breast CancerCorona Virus InfectionER Positive Breast CancerEndometrial CancerHER2-negative Breast CancerOvarian Cancer

Phase 1

Intravenous Zotatifin in Adults With Mild or Moderate COVID-19

CompletedNCT04632381

Effector TherapeuticsCorona Virus Infection

Start: 2021-07-01End: 2023-09-22Updated: 2023-10-05

Phase 2

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

RecruitingNCT03675893

Dana-Farber Cancer InstituteEndometrial Cancer, Ovarian Cancer

Start: 2018-12-24End: 2031-08-01Target: 180Updated: 2025-06-15

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

CompletedNCT05101564

Jennifer Lee Caswell-JinBreast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer

Start: 2023-03-20End: 2024-06-03Updated: 2026-02-12

Related Papers

Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.

2025-12-03

Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)–positive recurrent endometrial cancer (EC).

Journal of Clinical Oncology2025-05-283 citations